Glenmark Pharmaceuticals announced that its subsidiary, Glenmark Pharmaceuticals Inc., USA, will soon launch its 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) single-dose vial in the United States.
The product has been found bioequivalent and therapeutically equivalent to the reference listed drug, 8.4% Sodium Bicarbonate Injection, 50 mEq/50 mL (1 mEq/mL) of Abbott Laboratories Pharmaceutical Products Division (NDA 019443).
Glenmark plans to begin distribution in November 2025, marking another step in expanding its injectables portfolio within the U.S. market.
According to IQVIA sales data for the 12-month period ending August 2025, the market for 8.4% Sodium Bicarbonate Injection (50 mEq/50 mL; 1 mEq/mL) recorded annual sales of approximately $63.8 million.
The upcoming launch strengthens Glenmark’s commitment to providing high-quality, affordable injectable medicines for patients in the United States.
Also Read
